<VariationArchive VariationID="455787" VariationName="NM_004937.3(CTNS):c.206_210del (p.Ile69fs)" VariationType="Deletion" Accession="VCV000455787" Version="13" RecordType="classified" NumberOfSubmissions="4" NumberOfSubmitters="4" DateLastUpdated="2024-07-29" DateCreated="2017-08-27" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="467996" VariationID="455787">
      <GeneList>
        <Gene Symbol="CTNS" FullName="cystinosin, lysosomal cystine transporter" GeneID="1497" HGNC_ID="HGNC:2518" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>17p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="3636459" stop="3663103" display_start="3636459" display_stop="3663103" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="3539761" stop="3566396" display_start="3539761" display_stop="3566396" Strand="+" />
          </Location>
          <OMIM>606272</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_004937.3(CTNS):c.206_210del (p.Ile69fs)</Name>
      <CanonicalSPDI>NC_000017.11:3648911:TCCTT:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>17p13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="3552206" stop="3552210" display_start="3552206" display_stop="3552210" variantLength="5" positionVCF="3552205" referenceAlleleVCF="ATCCTT" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="3648912" stop="3648916" display_start="3648912" display_stop="3648916" variantLength="5" positionVCF="3648911" referenceAlleleVCF="ATCCTT" alternateAlleleVCF="A" />
      </Location>
      <ProteinChange>I69fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.3552206_3552210del" Assembly="GRCh37">
            <Expression>NC_000017.10:g.3552206_3552210del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004937.2" sequenceAccession="NM_004937" sequenceVersion="2" change="c.206_210del">
            <Expression>NM_004937.2:c.206_210del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.11" sequenceAccession="NC_000017" sequenceVersion="11" change="g.3648912_3648916del" Assembly="GRCh38">
            <Expression>NC_000017.11:g.3648912_3648916del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012489.2" sequenceAccession="NG_012489" sequenceVersion="2" change="g.17445_17449del">
            <Expression>NG_012489.2:g.17445_17449del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001031681.3" sequenceAccession="NM_001031681" sequenceVersion="3" change="c.206_210del">
            <Expression>NM_001031681.3:c.206_210del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001026851.2" sequenceAccession="NP_001026851" sequenceVersion="2" change="p.Ile69fs">
            <Expression>NP_001026851.2:p.Ile69fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374492.1" sequenceAccession="NM_001374492" sequenceVersion="1" change="c.206_210del">
            <Expression>NM_001374492.1:c.206_210del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001361421.1" sequenceAccession="NP_001361421" sequenceVersion="1" change="p.Ile69fs">
            <Expression>NP_001361421.1:p.Ile69fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374494.1" sequenceAccession="NM_001374494" sequenceVersion="1" change="c.-236_-232del">
            <Expression>NM_001374494.1:c.-236_-232del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004937.3" sequenceAccession="NM_004937" sequenceVersion="3" change="c.206_210del" MANESelect="true">
            <Expression>NM_004937.3:c.206_210del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_004928.2" sequenceAccession="NP_004928" sequenceVersion="2" change="p.Ile69fs">
            <Expression>NP_004928.2:p.Ile69fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374493.1" sequenceAccession="NM_001374493" sequenceVersion="1" change="c.-217+1390_-217+1394del">
            <Expression>NM_001374493.1:c.-217+1390_-217+1394del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374495.1" sequenceAccession="NM_001374495" sequenceVersion="1" change="c.-216-6086_-216-6082del">
            <Expression>NM_001374495.1:c.-216-6086_-216-6082del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374496.1" sequenceAccession="NM_001374496" sequenceVersion="1" change="c.-217+1390_-217+1394del">
            <Expression>NM_001374496.1:c.-217+1390_-217+1394del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA287009070" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="606272.0010" DB="OMIM" />
        <XRef Type="rs" ID="879758262" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00001" Source="Trans-Omics for Precision Medicine (TOPMed)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_004937.3(CTNS):c.206_210del (p.Ile69fs) AND Nephropathic cystinosis" Accession="RCV000004703" Version="12">
        <ClassifiedConditionList TraitSetID="1222">
          <ClassifiedCondition DB="MedGen" ID="C2931187">Nephropathic cystinosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-06-02" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004937.3(CTNS):c.206_210del (p.Ile69fs) AND Cystinosis" Accession="RCV001358753" Version="9">
        <ClassifiedConditionList TraitSetID="31961">
          <ClassifiedCondition DB="MedGen" ID="C4316899">Cystinosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-03-30" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004937.3(CTNS):c.206_210del (p.Ile69fs) AND multiple conditions" Accession="RCV002527666" Version="9">
        <ClassifiedConditionList TraitSetID="65712">
          <ClassifiedCondition DB="MedGen" ID="C0950123">Inborn genetic diseases</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0268626">Juvenile nephropathic cystinosis</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C2931013">Ocular cystinosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-01-27" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-01-27" NumberOfSubmissions="4" NumberOfSubmitters="4" DateCreated="2017-08-27" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10625078</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20061170</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27102039</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30554218</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9537412</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9792862</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1222" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="15909" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Nephropathic cystinosis</ElementValue>
                <XRef ID="54105" DB="GeneTests" />
                <XRef ID="MONDO:0100151" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Lysosomal cystine transport protein, defect of</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystinosin, defect of</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Abderhalden Lignac Kaufmann disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Abderhalden-Kaufmann-Lignac syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CTNS</ElementValue>
                <XRef ID="GTR000529128" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558532" DB="Genetic Testing Registry (GTR)" />
                <XRef Type="MIM" ID="219800" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10074" />
                <XRef ID="10074" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.</Attribute>
                <XRef ID="NBK1400" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301574</ID>
                <ID Source="BookShelf">NBK1400</ID>
              </Citation>
              <XRef ID="213" DB="Orphanet" />
              <XRef ID="411629" DB="Orphanet" />
              <XRef ID="C2931187" DB="MedGen" />
              <XRef ID="MONDO:0100151" DB="MONDO" />
              <XRef Type="MIM" ID="219800" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="65712" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="32761" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Inborn genetic diseases</ElementValue>
              </Name>
              <Citation Type="general" Abbrev="Langer et al., 2012">
                <ID Source="PubMed">22947299</ID>
              </Citation>
              <Citation Type="general" Abbrev="SACHDNC, 2013">
                <ID Source="PubMed">23037933</ID>
              </Citation>
              <Citation Type="general" Abbrev="EASAC/FEAM, 2013">
                <ID Source="PubMed">23169492</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESHG/P3G/HUGO/PHGF, 2015">
                <ID Source="PubMed">25626707</ID>
              </Citation>
              <Citation Type="general" Abbrev="Alpha-1 Foundation, 2014">
                <ID Source="PubMed">24121147</ID>
              </Citation>
              <Citation Type="general" Abbrev="NBSTRN, 2015">
                <ID Source="PubMed">24394680</ID>
              </Citation>
              <Citation Type="general" Abbrev="EUNENBS, 2014">
                <ID Source="PubMed">23652378</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2014">
                <ID Source="PubMed">23881473</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/ACOG/NSGC/PQF/SMFM, 2015">
                <ID Source="PubMed">25730230</ID>
              </Citation>
              <Citation Type="general" Abbrev="Skirton et al., 2014">
                <ID Source="PubMed">24022298</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23619275</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2019">
                <ID Source="PubMed">31022120</ID>
              </Citation>
              <XRef ID="C0950123" DB="MedGen" />
              <XRef ID="D030342" DB="MeSH" />
            </Trait>
            <Trait ID="1215" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Cystinosis, adult, nonnephropathic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystinosis, benign, nonnephropathic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystinosis, ocular nonnephropathic</ElementValue>
                <XRef ID="Cystinosis%2C+Ocular+Nonnephropathic/2080" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Ocular cystinosis</ElementValue>
                <XRef ID="MONDO:0009064" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9756" />
                <XRef ID="9756" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.</Attribute>
                <XRef ID="NBK1400" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301574</ID>
                <ID Source="BookShelf">NBK1400</ID>
              </Citation>
              <XRef ID="213" DB="Orphanet" />
              <XRef ID="411641" DB="Orphanet" />
              <XRef ID="C2931013" DB="MedGen" />
              <XRef ID="MONDO:0009064" DB="MONDO" />
              <XRef Type="MIM" ID="219750" DB="OMIM" />
            </Trait>
            <Trait ID="1216" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Juvenile nephropathic cystinosis</ElementValue>
                <XRef ID="Juvenile+nephropathic+cystinosis/8698" DB="Genetic Alliance" />
                <XRef ID="MONDO:0009066" DB="MONDO" />
                <XRef ID="22830006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CYSTINOSIS, LATE-ONSET JUVENILE OR ADOLESCENT NEPHROPATHIC TYPE</ElementValue>
                <XRef Type="MIM" ID="219900" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0016" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0018" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606272.0008" DB="OMIM" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17685" />
                <XRef ID="17685" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.</Attribute>
                <XRef ID="NBK1400" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301574</ID>
                <ID Source="BookShelf">NBK1400</ID>
              </Citation>
              <XRef ID="213" DB="Orphanet" />
              <XRef ID="411634" DB="Orphanet" />
              <XRef ID="C0268626" DB="MedGen" />
              <XRef ID="MONDO:0009066" DB="MONDO" />
              <XRef Type="MIM" ID="219900" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="31961" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6309" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Cystine diathesis</ElementValue>
                <XRef ID="D003554" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystine disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystine storage disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cystinoses</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Cystinosis</ElementValue>
                <XRef ID="3377" DB="GeneTests" />
                <XRef ID="MONDO:0016239" DB="MONDO" />
                <XRef ID="190681003" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.</Attribute>
                <XRef ID="NBK1400" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6236" />
                <XRef ID="6236" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301574</ID>
                <ID Source="BookShelf">NBK1400</ID>
              </Citation>
              <XRef ID="213" DB="Orphanet" />
              <XRef ID="C4316899" DB="MedGen" />
              <XRef ID="MONDO:0016239" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="24878" SubmissionDate="2017-08-23" DateLastUpdated="2017-08-27" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="606272.0010_CYSTINOSIS, NEPHROPATHIC" title="CTNS, 5-BP DEL, NT545_CYSTINOSIS, NEPHROPATHIC" />
        <ClinVarAccession Accession="SCV000024878" DateUpdated="2017-08-27" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1998-11-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Shotelersuk et al. (1998) identified a 5-bp deletion starting at nucleotide 545 resulting in an I69R amino acid substitution and a stop codon at position 73 of the CTNS gene in a patient with classic cystinosis (219800).</Attribute>
              <Citation>
                <ID Source="PubMed">9792862</ID>
              </Citation>
              <XRef DB="OMIM" ID="219800" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CTNS" />
          </GeneList>
          <Name>CTNS, 5-BP DEL, NT545</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">5-BP DEL, NT545</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="606272.0010" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">CYSTINOSIS, NEPHROPATHIC</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3061453" SubmissionDate="2021-04-07" DateLastUpdated="2021-04-13" DateCreated="2021-04-13">
        <ClinVarSubmissionID localKey="NM_004937.2:c.206_210delTCCTT|MedGen:C4316899" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001554609" DateUpdated="2021-04-13" DateCreated="2021-04-13" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-03-30">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9792862</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30554218</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10625078</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20061170</ID>
          </Citation>
          <Comment>Variant summary: CTNS c.206_210delTCCTT (p.Ile69ArgfsX5) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251456 control chromosomes. c.206_210delTCCTT has been reported as a homozygous mutation in at least one individual affected with Cystinosis (e.g. Shotelersuk_1998). These data indicate that the variant may be associated with disease. Fibroblasts from this patient were assessed as having higher levels of intracellular cystine compared to normal controls (e.g. Vitcitsky_2010). One other clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 and cited the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CTNS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004937.2:c.206_210delTCCTT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C4316899" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB9444141</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7867328" SubmissionDate="2023-12-07" DateLastUpdated="2023-12-30" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_004937.3:c.206_210del|OMIM:219800" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004215227" DateUpdated="2023-12-30" DateCreated="2023-12-30" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004937.3:c.206_210del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="219800" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1217953" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2017-12-26">
        <ClinVarSubmissionID localKey="2194030|MedGen:C0950123;C1857413;C0268626" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000625760" DateUpdated="2024-02-28" DateCreated="2017-12-26" Type="SCV" Version="6" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9537412</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27102039</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10625078</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Ile69Argfs*5) in the CTNS gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CTNS are known to be pathogenic (PMID: 9537412, 27102039). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with cystinosis (PMID: 10625078). ClinVar contains an entry for this variant (Variation ID: 455787). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CTNS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.3552206_3552210del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0950123" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1857413" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268626" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14224806</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3061453" TraitType="Disease" MappingType="XRef" MappingValue="C4316899" MappingRef="MedGen">
        <MedGen CUI="C4316899" Name="Cystinosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7867328" TraitType="Disease" MappingType="XRef" MappingValue="219800" MappingRef="OMIM">
        <MedGen CUI="C2931187" Name="Nephropathic cystinosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1217953" TraitType="Disease" MappingType="XRef" MappingValue="C0268626" MappingRef="MedGen">
        <MedGen CUI="C0268626" Name="Juvenile nephropathic cystinosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1217953" TraitType="Disease" MappingType="XRef" MappingValue="C1857413" MappingRef="MedGen">
        <MedGen CUI="C2931013" Name="Ocular cystinosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1217953" TraitType="Disease" MappingType="XRef" MappingValue="C0950123" MappingRef="MedGen">
        <MedGen CUI="C0950123" Name="Inborn genetic diseases" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="24878" TraitType="Disease" MappingType="Name" MappingValue="CYSTINOSIS, NEPHROPATHIC" MappingRef="Preferred">
        <MedGen CUI="C2931187" Name="Nephropathic cystinosis" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

